Terminated PHASE1 INTERVENTIONAL 3-arm NCT02914938

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL

Sponsor: MEI Pharma, Inc.

Conditions Chronic Lymphocytic Leukemia (CLL) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) High Grade Non-Hodgkin's Lymphoma Mantle Cell Lymphoma (MCL) Marginal Zone B Cell Lymphoma Small Lymphocytic Lymphoma (SLL)

Interventions ME-401 Rituximab Zanubrutinib

Updated 22 times since 2017 Last updated: May 5, 2023 Started: Oct 31, 2016 Primary completion: Mar 29, 2023 Completion: Mar 29, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

discontinuation of zandelisib program

Other terminated trials from MEI Pharma, Inc.

More terminations from MEI Pharma, Inc.

Other Chronic Lymphocytic Leukemia (CLL) trials with similar outcome

Browse all Chronic Lymphocytic Leukemia (CLL) trials

This PHASE1 trial investigates Chronic Lymphocytic Leukemia (CLL) and Diffuse Large B-cell Lymphoma (DLBCL) and is currently terminated or withdrawn. MEI Pharma, Inc. leads this study, which shows 22 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

22 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jun 2023 — Jul 2024 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated
Feb 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE1
Sep 2022 — Feb 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 17 earlier versions

Jan 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Feb 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Sep 2020 — Dec 2020 [monthly]

Recruiting PHASE1
Jul 2020 — Sep 2020 [monthly]

Recruiting PHASE1
Apr 2020 — Jul 2020 [monthly]

Recruiting PHASE1
Jan 2020 — Apr 2020 [monthly]

Recruiting PHASE1
Jun 2019 — Jan 2020 [monthly]

Recruiting PHASE1
Jul 2018 — Jun 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2018 — Mar 2018 [monthly]

Recruiting PHASE1
Aug 2017 — Jan 2018 [monthly]

Recruiting PHASE1
Jun 2017 — Aug 2017 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MEI Pharma, Inc.

Data source: MEI Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Basking Ridge, United States , Bellinzona, Switzerland , Boston, United States , Cleveland, United States , Commack, United States , Corona, United States , Dallas, United States , Edmonds, United States , Harrison, United States , Houston, United States and 12 more locations